Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
aduhelm | Biologic Licensing Application | 2023-08-31 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
alzheimer disease | EFO_0000249 | D000544 | F03 |
Code | Description |
---|---|
J0172 | Injection, aducanumab-avwa, 2 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | 5 | 1 | 5 | — | 1 | 12 |
Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | 1 | 1 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dementia | D003704 | EFO_0003862 | F03 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Drug common name | Aducanumab |
INN | aducanumab |
Description | Aducanumab (human mab) |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | >6CNR:H|Aducanumab heavy chain
QVQLVESGGGVVQPGRSLRLSCAASGFAFSSYGMHWVRQAPGKGLEWVAVIWFDGTKKYYTDSVKGRFTISRDNSKNTLY
LQMNTLRAEDTAVYYCARDRGIGARRGPYYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP
VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
>6CNR:L|Aducanumab light chain
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQSYSTPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
PDB | 6CNR, 6CO3 |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3039540 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB12274 |
UNII ID | 105J35OE21 (ChemIDplus, GSRS) |